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CancerMitochondria are a major source of intracellular reactive oxygen species, the production of which increases
with cancer. The deleterious effects of reactive oxygen species may be responsible for the impairment of
mitochondrial function observed during various pathophysiological states associated with oxidative stress
and cancer. These organelles are also targets of oxidative damage (oxidation of mitochondrial DNA, lipids,
protein). An important factor for protein maintenance in the presence of oxidative stress is enzymatic reversal
of oxidative modiﬁcations and/or protein degradation. Failure of these processes is likely a critical component
of the cancer process. Mitochondrial proteases degrade misfolded and non-assemble polypeptides, thus
performing quality control surveillance in the organelle. Mitochondrial proteases may be directly involved in
cancer development as recently shown for HtrA2/Omi or may regulate crucial mitochondrial molecule such as
cytochrome c oxidase 4 a subunit of the cytochrome c oxidase complex degraded by the Lon protease. Thus,
the role of mitochondrial proteases is further addressed in the context of oxidative stress and cancer. This
article is part of a Special Issue entitled: Bioenergetics of Cancer.xia inducible factor; IM, inner
mtDNA, mitochondrial DNA;
plex; PDZ, PDZ domain; PHD,
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Functional integrity and rapid and appropriate responses to
physiological and pathophysiological stimuli are required for mito-
chondria to meet cellular energy demands. In addition, mitochondria
participate in cellular Ca2+ homeostasis, signaling cascades [1].
Mitochondria are cell organelles involved in the processes of cell
life and death and therefore also in tumoral transformation [2,3].
Indeed, mitochondria dysfunction is a prominent feature of cancer
cells. The mitochondrial respiratory chain is one of the main sources
of endogenous reactive oxygen species and mitochondrial proteins
represent targets for oxidative modiﬁcation and loss in function [4,5].
More recent evidence indicates the importance of hypoxia and
stressful conditions of nutrient (lack of glucose) in cell proliferation
[6]. These two factors can promote the process of malignant
transformation. It is apparent that hypoxia can cause the progressive
elevation in mitochondrial ROS production that can target mt DNA
and drive the malignant transformation process. Mitochondrial
proteins and DNA have also been previously studied as markers oftumorigenesis [2,3]. Old or damaged mitochondria that produce high
levels of ROS are normally degraded by mitophagy [7,8]. Degradation
of oxidized protein in the mitochondria can prevent the induction of
tumorigenesis [9]. In the cytosol, the proteasome constitutes the main
proteolytic machinery involved in the elimination of oxidized protein
[10]. However, this proteolytic complex is not present in the
mitochondria. Pioneering studies have shown that mitochondrial
matrix from liver and heart contains proteolytic activity that degrades
oxidized, dysfunctional, and misfolded protein [11]. More recent
work supports a role for the mitochondrial matrix Lon protease in
eliminating oxidatively modiﬁed mitochondrial proteins [12], similar
to the role of the proteasome in the cytosol (Table 1). We review here
the current evidence that Lon protease can directly or indirectly be
involved in tumorigenesis. Two other mitochondrial proteases have
received great attention in the last few years for their potential in cell
proliferation, the HtrA2/Omi and prohibitin complexes. They will be
discussed here because of some similarities in the way they affect cell
apoptosis.
2. Emerging role of the mitochondrial Lon protease in cancer
2.1. The Lon protease: from protein control to regulatory function
Mammalian mitochondria contain four major ATP-dependent
proteases, Lon, Clp-like, and AAA proteases. Clp-like and AAA
proteases are hetero-oligomeric complexes located in the matrix
and inner mitochondrial membrane, respectively [13]. As evidenced
by various mutational studies, these proteases contribute to the
Table 1
Physiological substrates of mitochondrial proteases.
Lon protease Degradation of oxidatively modiﬁed or misfolded proteins Aconitase [16], Atp1, Atp2, Atp7, Rip1, Qcr2, Pdb1, Lat1, Lpd1, Kgd2, Ilv5 [81]
mt DNA replication, transcription, maintenance [46,89,90]
Composant of the mitochondrial nucleoid Selective degradation of TFAM [91].
Hypoxia Degradation of cytochrome C oxidase COX4-1 subunit [37,92].
Cholesterol metabolism Star protein [93].
HtrA2/Omi Induction of apoptosis XIAP [94], Apollon/BRUCE [101], WT1 [55,56]
Induction of apoptosis Ped/Pea-15 [95]
Cytoskeleton protein Actin, Tubulin-α, β-vimentin [96]
Translation machinery EF1-α [96]
Prohibitin (PHB complex) Assembly/stabilization of OXPHOS complex OXPHOS complex [97], F1/F0 ATPase [98]
Component of mt DNA nucleoid [84]
Protein degradation/associationwith m-AAA protease [15]
m-AAA protease Respiratory complex components [97,98]
Ribosome assembly Mrlp32 [99]
Mitochondrial dynamic Opa1 [100]
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nance of mitochondrial genome stability. In addition, both proteolytic
systems appear to exert chaperone activity. The physiological function
of Clp-like protease, however, is yet to be determined. Currently,
information regarding the regulation of each of the ATP-dependent
proteases and/or the identities of speciﬁc protein substrates is limited.
Nevertheless, exposure of hydrophobic residues is likely a common
recognition element and both chaperone and proteolytic functions
participate in prevention of the accumulation of aggregated material
[14,15]. The Lon protease plays a critical role in the removal of
oxidized protein and damage (Fig. 1). Aconitase, a Krebs cycle enzyme
known to be susceptible to oxidative inactivation, has been shown to
be a substrate of the Lon protease when the enzyme is inactivated
upon treatment with oxygen radicals [12]. Indeed, the matrix
proteolytic activity responsible for the selective degradation ofFig. 1. Mitochondrial protein quality control in the matrix compartment. In the early stag
promoting ROS production. Protein become misfolded due to oxidative stress conditions
accumulation andmitochondria injury. In conditions of excessive damage, oxidative modiﬁc
favor carcinogenesis only when senescence program is inactivated.oxidatively modiﬁed aconitase was strongly stimulated by ATP and
inhibited by the serine protease inhibitor PMSF. In addition, the same
proteolytic activity co-puriﬁed with the Lon protease after size
exclusion chromatography and afﬁnity chromatography of the
mitochondrial matrix fraction. Moreover, both puriﬁed Lon protease
and mitochondrial matrix extracts exhibited similar activation and
inhibition proﬁles. Treatment with anti-sense oligonucleotides in WI-
38 human lung ﬁbroblasts resulted in decreased Lon protease content
and activity while causing an accumulation of oxidatively modiﬁed
aconitase [16]. More recently, it has been shown that downregulation
of the human Lon protease results in disruption of mitochondrial
structure, loss in function, and cell death, with the majority of cells
undergoing caspase 3 activation and apoptosis within four days [17].
Electron microscopy performed on Lon-deﬁcient cells revealed
aberrant mitochondrial morphology and the presence of electrones of tumorigenesis hypoxia and glucose deprivation alter mitochondrial function by
and tend to aggregate. By degrading oxidized protein, Lon protease prevents their
ation of mitochondrial protein can trigger senescence. Mitochondrial dysfunction would
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represent oxidatively modiﬁed and aggregated protein [17]. Taken
together, these ﬁndings argue for an important role of the Lon
proteolytic system for the degradation of oxidized protein within the
mitochondrial matrix and for the maintenance of mitochondrial
structural and functional integrity (Fig. 1).
2.2. Structure and functions of the Lon mitochondrial protease
As are numerous mitochondrial proteins, the Lon protease is
encoded by the nuclear genome (Fig. 2). The lon gene encodes a 963
amino acid protein [18] homologous to the bacterial protease La. This
protease is active as an homo-oligomeric complex composed of 6
monomers in Escherichia coli and 7 monomers in eukaryotes such as
yeast with a molecular weight of approximately 106 kDa. The Lon
protease is composed of three domains that are conserved within the
different species [19]. The N-terminal domain (domain N) is capable
of interacting with protein substrates in concert with the second
domain, also termed the AAA+ module. The AAA+ module is
composed of two segments, one involved in ATP binding (α/β
domain) and the other in ATP hydrolysis (α domain). A third domain
(P domain) carries the Serine and Lysine active site residues that form
the catalytic dyad for proteolytic activity [20]. The identity of these
active site residues was ﬁrst evidenced by a comparison of the
different Lon protease protein sequences and further conﬁrmed by a
site directed mutagenesis analysis and elucidation of the three
dimensional structure of the E. coli Lon protease P domain [21–23].
Interestingly, the isolated P domain does not exhibit any proteolytic
activity towards protein substrates such as casein but is capable of
degrading small peptides such as melittin [24]. The three dimensional
structure of both the N and AAA+ domains of the E. coli Lon protease
has also been recently solved [23]. While the manner by which
protein substrates bind to the Lon protease remains to be elucidated,
it has been proposed that exposed loops at the surface of substrate
proteins are essential features for recognition [19]. The Lon protease
acts as a serine protease that undergoes the formation of an acyl-
enzyme intermediate with a cleavage speciﬁcity that would be similar
to that of chymotrypsin, allowing proteolysis at the C-terminus of
hydrophobic amino acids such as methionine, tyrosine, and trypto-
phan [25]. An important feature of the proteolytic activity of Lon is its
stimulation by ATP. In contrast, ADP acts as an inhibitor of the
protease indicating regulation in response to changes in energy
charge [26]. In addition to its proteolytic activity, mammalian Lon has
also been shown to display chaperone properties and to speciﬁcally
bind sequences of human mitochondrial DNA and RNA, as well as to
interact with mitochondrial DNA polymerase γ and the twinkleFig. 2. Schematic representation of domain organization of human Lon protease and Htra2/
associated with various cellular activities; α/β domain, ATP binding site; α domain, ATP
domain, inhibitor of apoptosis (IAP-binding motif); S1 protease, trypsin-like protease domahelicase [27]. It has been shown that Lon downregulation in WI-38
human lung ﬁbroblasts elicits two temporally and mechanistically
distinctive patterns. Initially, loss of Lon activity causes massive
apoptosis, with the classic hallmark of caspase-3 activation. At this
early stage cell survival can only be improved by addition of caspase-3
inhibitor. Two Lon functions seem to be mostly involved in this early
apoptosis: the proteolytic defect causes accumulation of aggregated
proteins inside mitochondria, while loss of chaperone function
severely affects mitochondrial respiration and membrane potential,
rendering cells extremely susceptible to apoptotic stimuli. At a later
stage, the surviving cells lose their ability to undergo apoptosis and
are respiratory deﬁcient and unable to divide due to defects in uridine
synthesis [17].
2.3. Suppression of mitochondrial activity in cancer cell: regulation
of cytochrome c oxidase activity by HIF-1 and Lon protease
In some forms of cancer, analysis of possible alterations in the
oxidative phosphorylation machinery revealed downregulation of the
catalytic subunit of the mitochondrial ATP synthase. It was found to
inversely correlate with the rate of aerobic glycolysis [6].
Fast proliferation is one of the main characteristics of cancer cells.
This leads to hypoxia in tumors due to inability to provide adequate
oxygenation. Hypoxic conditions are usually lethal to non malignant
cells due to hypoxia-mediated P53 dependent cell death [28]. Due to
the inability of the mitochondria to provide enough ATP for cell
survival under hypoxic conditions tumor cells must upregulate the
glycolitic pathway. This occurs via induction of HIF-1 factor (hypoxia-
inducible factor). HIF plays an important role in the metazoan
response to low oxygen levels (hypoxia) [29]. HIF is a heterodimeric
transcription factor; in human cells, levels of the HIF-α domain are
regulated in an oxygen-dependent manner by four enzymes, known
as the HIF hydroxylases [30–33]. Under normal oxygen conditions,
these enzymes catalyze hydroxylation of two prolyl residues in HIF-α
(Pro402 and Pro564) targeting them for ubiquitination and degradation
by the proteasome [34]. HIF induces genes that control crucial features
of cancer biology.
HIF can modulate mitochondrial functioning by its involvement in
the regulation of cytochrome oxidase (COX) expression. COX is a
dimer composed of 13 subunits. Mammalian cells express a
predominant COX4-1 isoform [35] (Fig. 3). Another isoform COX4-2
is also expressed but only in some tissues such as lung [36]. Under
hypoxia, its expression is increased whereas the other isoform
expression is decreased. Degradation of COX4-1 isoform occurs via
activation of the Lon protease [37]. This switch between the two
isoforms provides a mechanism to maintain the efﬁciency ofOmi. Abbreviations: N, N-terminal domain (interaction with substrates); AAA, ATPase
hydrolysis domain; P domain, proteolytic domain; TM, transmembrane domain; IBM
in; PDZ, PDZ domain.
Fig. 3. Implication of Lon protease and prohibitin in cancer. Prohibitin form a complex in the mitochondrial inner membrane. They may assist with protein folding and assembly. The
association of prohibitin with mitochondrial nucleoid and Lon protease may assure protection and regulation of mt DNA. Under aerobic conditions, mammalian cells express COX4-1
subunits whereas under hypoxic conditions, they express COX4-2, respectively. The change in subunit composition provides a mechanism by which mitochondrial respiration is
optimized according toO2 concentration. Degradation of COX4-1 subunits via activation of the Lon protease provides amechanism tomaintain the efﬁciency of respiration in tumor cells.
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involved in the adaptive response to hypoxia. Remarkably, Lon gene
expression is induced in response to hypoxia and multiple HIF-1
binding sites were identiﬁed in the 5-ﬂanking region of the human
gene LON gene by chromatin immunoprecipitation and reporter-gene
transcriptional assays [37]. Thus HIF-1 mediates co-ordinate regula-
tion of COX4-1 and COX4-2 subunit expression in response to changes
in O2 availability. The regulated expression of these subunits results in
a signiﬁcant decreases in O2 consumption.
2.4. Mitochondrial genome changes in cancer and involvement of
Lon protease
The mitochondrial genome in human cell is extremely small
(16,569 bp) compared to the nuclear DNA although every mitochon-
dria contains between 2 and 20 copies of mt DNA and the copy
number of mitochondrial genome per cell ranges from several
hundreds to more than 10,000 depending on the cell type. The
identiﬁcation of increased or reduced mt DNA content has been
reported in cancer cells [38]. Mt DNA is located in close proximity to
the respiratory chain and exposed to ROS-induced oxidative damage
[39]. Mt DNA includes a short segment of three strands called D loop.
This loop is the control region where replication and transcription
occur. Replication involves DNA polymerase γ as well as TFAM, one
of the three transcription factors [40]. In the past decade, many
groups have demonstrated that mt DNA mutations occur in a variety
of cancers and sequences of the D loop where Lon protease and
TFAM are binding are hot spot [41]. This is reﬂected in the higher
frequency of mt DNA mutations in somatic cells and signiﬁcantly
correlates with the development of cancer [42]. Mutations in the Pol
γ exonuclease activity domain are known to promote large deletionin mt DNA. The concomitant presence of somatic alterations in mt
DNA and mutation of the DNA binding domain of p53 in cancers
have been noted and proposed to facilitate cell survival and
tumorigenesis [43]. This also supports that dysfunction of mitochon-
drial respiration in patients with cancers facilitates tumor growth
through ROS production.
Alongside protease activity Lon regulates the replication of
mitochondrial DNA. Mammalian Lon binds single strands DNA with
speciﬁcity for a G-rich consensus sequence. Previous studies show
that ATP blocks Lon binding to mtDNA [27,44–46]. Investigating the
role of Lon in the protection of mt DNA is challenging and needs
further research. Stimulation of its binding activity to mt DNA should
prevent initiation of tumorigenesis (Fig. 3).
3. HtrA2/Omi, a new target in cancer therapy
Themembers of the HtrA family of proteases play important role in
cell physiology and are involved in several pathological processes
including cancer and neurodegenerative diseases [47]. Members of
the HtrA family are present in nearly all bacterial and eukaryotic
genomes. Whereas HtrA2/Omi resides in the mitochondrial inter-
membrane space, its paralogs HTRA1, 3, and 4 are mostly targeted
to the secretory pathway. There are several indications of HtrA2
involvement in oncogenesis. It is widely expressed in a variety of
cancer cell lines [48–51]. Analysis of biopsy samples showed
changes in expression of HtrA2 in cancer tissues compared with
normal tissues. The serine protease HtrA2/Omi is involved in the
regulation of apoptosis and is principally found in the mitochondria,
although a fraction is also located in the nucleus [47]. HtrA2 serves
as a protein quality control and increase of its proteolytic activity via
allosteric ligands mimicking peptides could improve effects of
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consists of a chymotrypsin-like proteolytic domain with catalytic
triad Ser-His-Asp and one PDZ domain. PDZ domains have been
shown to act as regulatory elements and as speciﬁcity determinants
[53,54] (Fig. 2). The proteolytic activity of HtrA2 can be stimulated
by several apoptotic stimuli, and substrates include members of the
inhibitors of apoptosis family (IAPs) (reviewed in reference 47). In a
recent study, Hartkamp et al. [55] identify the serine protease HtrA2
as a WT1-interacting protein and demonstrate that it can degrade
WT1. They showed that endogenous WT1 in tumor cells is cleaved
following cytotoxic drug treatment and demonstrate that this
cleavage is HtrA2 dependent. These ﬁndings suggest that HtrA2 is
a critical regulator of WT1 under proapoptotic conditions [55,56].
4. Role of prohibitin in cell proliferation
4.1. The mitochondrial prohibitin complex (PHB)
PHB are considered to be involved in regulation of the cell cycle
[57,58], apoptosis [59,60], and senescence [61,62] and are chaperones
to mitochondrial proteins [63]. Prohibitins primary function is to
stabilize new synthesized polypeptides in mitochondria, as they serve
as foldase unfoldase molecular chaperones [63]. Phb1p and Phb2p
localize in the inner mitochondrial membrane (IM) forming a 1MD
complex, composed of 14 subunits (hPhb1p, 32 kDa; hPhb2p, 34 kDa)
in a 1:1 ratio [64] (Fig. 3). The substrates of the PHB complex are not
known in details yet, but the most important seem to be electron
chain transport subunits [65]. It seems that PHBs are negative
regulators of m-AAA-proteases and PHBs stabilize m-AAA proteases
in low activity conformation [63]. PHBs are also able to modulate
accessibility and conformation potential substrates of proteases [66].
PHBp have also been recognized as negative regulators of cell cycle. It
was established that PHBs are overexpressed in metabolic stress,
when the mtDNA/nDNA balance is altered, after heat shock or
oxidative stress [67,68].
4.2. Prohibitin 1 as a tumor suppressor
The eukaryotic mitochondrial PHB comprises two highly homol-
ogous subunits, PHB1 and PHB2 (around 50% amino acid sequence
identity and 60% similarity). The ﬁrst mammalian prohibitin PHB1
was identiﬁed as a potential tumor suppressor with antiproliferative
activity and hence was named prohibitin [69]. Extensive and rapidly
accumulating evidence suggests that both prohibitins function within
mitochondria [70,71]. Cell fractionation of rat liver showed almost all
of the prohibitin proteins to be localized in mitochondria, with some
protein in the lysosomal and ribosomal fractions and none in the
cytoplasm. Observed nuclear localization was traced back to con-
taminations during preparation [69]. Nevertheless, Fusaro et al. [59]
appear to have identiﬁed a nuclear localization for prohibitin 1 in two
breast cancer cell lines—MCF-7 and T47D cells. Upon camptothecin
induced apoptosis prohibitin 1 translocates from the nucleus to the
mitochondria [60]. While overexpressed but not mutated prohibitin 1
is found in a relevant percentage of cancers [72], the human prohibitin
1 gene is a candidate tumor suppressor locus that maps to a region of
chromosome 17 (17q21) commonly deleted or mutated in breast
tumors [73]. Research on prohibitin started out in the early nineties
with the discovery of its anti-proliferating function when micro-
injected into ﬁbroblasts [74]. This attribute was later ascribed to its 3′
UTR, thus assigning it to the novel class of non coding RNAs. The
importance of the 3′UTR for regulating proliferation was demonstrat-
ed when point mutations in this region were found in a relevant
number of cancers [74]. However, numerous studies contradicted
these ﬁndings, showing no relevance of prohibitin polymorphisms to
breast cancer risks [75,76]. At the same time, the protein itself is still
the subject of intensive research, which attempts to clarify its functionas a tumor suppressor. Wang et al. [58] report that prohibitin 1
interacts with pRb and regulates E2F function.
4.3. Prohibitins function as mitochondrial chaperones of m-AAA
proteases and interaction with Lon protease
As already indicated, prohibitins perform a role as mitochondrial
chaperones. Furthermore, mitochondria occupy the central focus in
apoptotic signaling processes, therefore potentially providing the
stage for the apoptotic function of prohibitins [67]. As for most
mitochondrial proteins, such as members of the mitochondrial
import machinery, research to identify the role of prohibitins in
mitochondria was mainly performed in yeast. Nijtmans et al. [77]
were the ﬁrst to show that prohibitins form a complex in the
mitochondrial inner membrane. Multimeres, consisting of 16–20
prohibitin molecules and presumably linked by their C-terminal
coiled coil domains, act as chaperones to stabilize mitochondrial
proteins and facilitate respiratory complex assembly [77]. Additional
work by Tatsuta et al. [64] showed that this complex was circularly
arranged around the m-AAA protease (Figs. 1 and 3). The AAA
proteases are ATP dependent proteases (ATP-associated with diverse
cellular activity) of the inner mitochondrial membrane. Their
proteolytic domains have metal-dependent peptidase activity [78].
While the active site of the i-AAA protease reaches into the inter-
membrane space, m-AAA exposes its catalytic site towards the
matrix (Figs. 1 and 3). In yeast, on which most of the studies were
done, the m-AAA protease consists of two subunits, Yta10p and
Yta12p, and regulates the turnover of non-assembled inner mem-
brane proteins [15]. Their homologues in vertebrates are paraplegin
and AFG3L2, respectively [79]. This complex stabilizes newly
synthesized mitochondrial translation products [64,65]. While the
deletion of one of the m-AAA subunits leads to an impaired
degradation of non-assembled inner membrane proteins and an
impaired assembly of respiratory chain complexes, the deletion of
either Phb1p or Phb2p leads to an accelerated turnover of these
proteins [63]. Our results show that Lon protease could be recruited
to the inner membrane of mitochondria and interact with the
prohibitins [80,81]. These ﬁndings indicate that prohibitins interact
with Lon protease, could serve as a recruiter complex in the inner
membrane to assist the quality control of membrane proteins by Lon
protease, and maintain of mtDNA metabolism. Prohibitin has been
reported to be involved in the mitochondrial nucleoid complex
[82,83]. In a recent study, prohibitin 1 has been shown to be
involved in the maintenance of the mitochondrial nucleoid organi-
zation by TFAM-independent pathway and regulation of mtDNA
copy number by TFAM-dependent pathway [84]. It is possible that
prohibitin 1 directly maintains the mitochondrial nucleoid organi-
zation by its interaction with the Lon protease which binds mt DNA
and regulate TFAM expression. Protection of mitochondrial DNA
from oxidative damage can therefore prevent cellular transformation
and accelerated proliferation.
5. Conclusions and future directions
In conclusion, Lon protease emerges as a major controller of
multiple human mitochondrial functions, including the assembly of
respiratory chain protein complexes, the degradation of damaged
proteins, the interaction with prohibitin, and the maintenance of
mitochondrial DNA integrity.
Only a few speciﬁc substrates of Lon protease have been identiﬁed
in mammalian systems [15,85]. Lon homeostasis is crucial to
mammalian cell fate, as Lon upregulation is associated with
tumorigenic transformation [86,87] and its downregulation leads to
apoptosis [17]. Thus, further studies in animal systems are needed to
explain the speciﬁc pathways controlled by Lon and to develop an
advanced understanding of Lon involvement in apoptosis and cancer.
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increasing the rates of biogenesis of mammalian mitochondria either
by neoplastic transformation or rapid cell growth. The rapid growth
and division of cancer cells induce a disproportionate expression of
some unassembled subunits that are subjected to degradation by the
Lon protease. This scenario ﬁts with the enhanced expression of the
mitochondrial genome observed in rapidly growing neoplastic cells
and with the increased turnover of mitochondrial protein in rapidly
growing cells [2]. Taken together, these data underscore the
important role of mitochondrial proteases in both mitochondrial
protein maintenance and cellular redox homeostasis through regu-
lated degradation of oxidatively modiﬁed proteins. It is increasingly
apparent that pro-oxidants do not simply cause damage but can
regulate protein function in a reversible fashion [85]. Future studies
must explore the delicate balance between these two opposing
effects. The speciﬁc role of Lon in these processes, physiological
substrates, and mechanisms of pro-oxidant induced activation must
be established [88]. Development of speciﬁc inhibitors and substrates
of the various mitochondrial proteases will hasten these discoveries
[80]. In addition, conditions that adversely affect the removal of
oxidatively modiﬁed protein must be deﬁned. Thus, critical risk
factors that shift the balance from reversible to irreversible loss in
mitochondrial and cellular function may be identiﬁed.
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